股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 江蘇中慧元通生物科技股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02627 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 296,361,845 RMB | | | 1 RMB | | 296,361,845 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 296,361,845 RMB | | | 1 RMB | | 296,361,845 | | 2. 股份分類 | 普通股 | 股份類別 | 其他類 ...

企业资讯 海普瑞(09989.HK)：预计2025年净利润2.84亿元-3.77亿元，同比下降41.71%-56.09%。 大唐发电(00991.HK)：2025年累计完成上网电量约2731.092亿千瓦时，同比上升约1.41%。 长城汽车(02333.HK)：2025年营业总收入2227.9亿元，同比增长10.19%；净利润99.12亿元。 中金公司(03908.HK)：预计2025年净利润85.42亿元到105.35亿元，同比增加50%到85%。 大唐发电(00991.HK)：预计2025年净利润为约68亿元至78亿元，同比增加约51%至73%。 荣昌生物(09995.HK)：预计2025年度营业收入约人民币32.5亿元，同比增加约89%；净利润约人民币 7.16亿元，实现扭亏为盈。 君实生物(01877.HK)：预计2025年年度实现营业收入25亿元左右，同比增长28.32%左右；净亏损为8.73 亿左右，同比亏损减少31.85%左右。 2月2日，港股早盘低开低走午后跌幅持续扩大，尾盘股指小幅回升跌幅缩窄，截止收盘，恒生指数跌 2.23%报26775.57点，恒生科技指数跌3.36%报5526.31点， ...

Major Events - Lanke Technology (06809) will conduct an IPO from January 30 to February 4, with an expected listing on February 9 [1] - Aixin Yuanzhi (00600) will conduct an IPO from January 30 to February 5, with an expected listing on February 10 [1] - Lexin Outdoor (02720) will conduct an IPO from January 31 to February 5, raising HKD 130 million from Horizon Capital and Huangshan Dejun [1] - Dongpeng Beverage (09980) sets the offer price at HKD 248 per share [1] - Zhonghui Biotech-B (02627) received approval from the National Medical Products Administration for a trivalent influenza virus subunit vaccine [1] - Kangzheng Pharmaceutical (00867) received approval for the first and only targeted drug for vitiligo treatment in China [1] - Shishi Pharmaceutical Group (02005) received production registration for Propafenone Hydrochloride Injection from the National Medical Products Administration [1] - China Aluminum (02600) plans to jointly acquire 68.6% of Brazilian Aluminum from Rio Tinto and will initiate a mandatory offer [1] - Yanzhou Coal Mining (01171) plans to transfer 100% equity of Inner Mongolia Xintai Coal [1] - Botai Car Union (02889) plans to collaborate with Ping An Property & Casualty to reconstruct the smart travel insurance ecosystem [1] - Jin Jing New Energy (01783) signed a strategic framework agreement with Tianqi Grand for lithium battery recycling and precious metal extraction [1] - Guangdong-Hong Kong-Macau Holdings (01396) subsidiary Hongce Data introduces Fudian Capital as a strategic investor for 40% equity [1] - China Mobile (00941), China Unicom (00762), and China Telecom (00728) will adjust the applicable scope of value-added tax for telecom services [1] Operating Performance - BYD Company (01211) sold approximately 210,000 new energy vehicles in January [2] - Geely Automobile (00175) reported total vehicle sales of 270,200 units in January, a year-on-year increase of about 1% [2] - Chery Automobile (09973) saw total sales of 191,500 vehicles in January, a year-on-year decrease of about 10.7% [2] - Seres (09927) reported total vehicle sales of 45,900 units in January, a year-on-year increase of 104.85% [2] - Great Wall Motors (02333) sold approximately 90,300 vehicles in January, a year-on-year increase of 11.59% [2] - Li Auto-W (02015) delivered 27,668 new vehicles in January, a year-on-year decrease of 7.5% [2] - NIO-SW (09866) delivered 27,182 vehicles in January, a year-on-year increase of 96.1% [2] - GAC Group (02238) reported vehicle sales of 116,600 units in January, a year-on-year increase of 18.47% [2] - Great Wall Motors (02333) released a preliminary report indicating a net profit attributable to shareholders of 9.912 billion yuan for 2025, a year-on-year decrease of 21.71% [2] - Shandong Gold (01787) expects a net profit attributable to shareholders of approximately 4.6 billion to 4.9 billion yuan for 2025, a year-on-year increase of 56% to 66% [2] Earnings Forecast - SF Express (09699) expects a year-on-year profit increase of no less than 80% for 2025 [3] - China International Capital Corporation (03908) anticipates a net profit attributable to shareholders of 8.542 billion to 10.535 billion yuan for 2025, a year-on-year increase of 50% to 85% [3] - China Shenhua (01088) expects a year-on-year decline in net profit for 2025 [3] - Datang Power (00991) anticipates a net profit of approximately 6.8 billion to 7.8 billion yuan for 2025, a year-on-year increase of about 51% to 73% [3] - China Southern Airlines (01055) expects a net profit attributable to shareholders of 800 million to 1 billion yuan for 2025, turning a profit [3] - Air China (00753) warns of a net loss attributable to shareholders of approximately 1.3 billion to 1.9 billion yuan for 2025 [3] - China Eastern Airlines (00670) warns of a net loss attributable to shareholders of approximately 1.3 billion to 1.8 billion yuan for 2025 [3] - GAC Group (02238) expects a net loss attributable to shareholders of 8 billion to 9 billion yuan for 2025 [3] - Ansteel (00347) warns of a net loss attributable to shareholders of approximately 4.077 billion yuan for 2025, a year-on-year narrowing of 42.75% [3] - Junshi Biosciences (01877) warns of a net loss attributable to shareholders of approximately 873 million yuan for 2025, a year-on-year decrease of about 31.85% [3]

Company News - Great Wall Motors (02333.HK) expects a total revenue of RMB 222.79 billion in 2025, representing a year-on-year increase of 10.19%. However, net profit is projected to decline by 21.71% to RMB 9.912 billion due to increased investments in new user channels and marketing for new models and technologies [2] - China Southern Airlines (01055.HK) anticipates turning a profit in 2025, with net profit expected to be between RMB 800 million and RMB 1 billion [2] - CICC (03908.HK) forecasts a net profit of RMB 8.542 billion to RMB 10.535 billion in 2025, reflecting a year-on-year increase of 50% to 85% [3] - Datang Power (00991.HK) projects a net profit of approximately RMB 6.8 billion to RMB 7.8 billion in 2025, indicating a year-on-year increase of about 51% to 73% [4] - Rongchang Bio (09995.HK) expects 2025 revenue of approximately RMB 3.25 billion, a year-on-year increase of about 89%, and a net profit of around RMB 716 million, achieving profitability [4] - Haijia Medical (06078.HK) anticipates revenue of approximately RMB 4.0 billion to RMB 4.05 billion in 2025, a year-on-year decrease of about 9% to 10%, with net profit expected to decline by 66% to 76% to around RMB 140 million to RMB 200 million [4] - Junshi Biosciences (01877.HK) expects 2025 revenue of around RMB 2.5 billion, a year-on-year increase of approximately 28.32%, with a net loss of about RMB 873 million, a reduction of 31.85% compared to the previous year [4] - Kaisa New Energy (01108.HK) issued a profit warning, expecting a year-on-year increase in net loss of approximately RMB 90.07 million to RMB 290 million [4] - Xingye Alloy (00505.HK) issued a profit warning, anticipating a year-on-year decrease in profit attributable to equity shareholders of about 50% [4] - Fudan Zhangjiang (01349.HK) issued a profit warning, expecting a net loss of approximately RMB 120 million to RMB 180 million in 2025 [4] - Chenming Paper (01812.HK) issued a profit warning, expecting a net loss of RMB 8.2 billion to RMB 8.8 billion, a significant increase compared to the previous year [5] - Tianqi Lithium (09696.HK) has commenced production of the first batch of standard chemical-grade lithium concentrate products from its third-phase expansion project [6] Financing and Buyback Activities - Xiaomi Group-W (01810.HK) repurchased approximately 4.2 million shares for about HKD 150 million, with repurchase prices ranging from HKD 35.13 to HKD 42.50 [10] - Vitasoy International (00345.HK) repurchased shares worth HKD 24.37 million, acquiring 3.492 million shares at prices between HKD 6.9 and HKD 7 [11] - Yujian Xiaomian (02408.HK) plans to repurchase up to HKD 100 million of H-shares [12] - Nanshan Aluminum International (02610.HK) completed a placement of 31 million shares, raising approximately HKD 1.987 billion [12]

近日，中慧生物-B(02627)迎来又一项里程碑式进展——全国首款且唯一的全人群三价流感病毒亚单位 疫苗成功获批上市。 此前，公司的四价流感亚单位疫苗(慧尔康欣)已率先实现全人群覆盖，成为中国首款且唯一一款获批上 市的全人群全剂量四价流感病毒亚单位疫苗。此次三价疫苗的成功获批，标志着公司在亚单位流感疫苗 这一优势赛道构建起更加全面的产品矩阵，不仅能够灵活适配多元化的公共卫生需求与市场偏好，也将 为公司业绩的持续兑现与价值重估注入强劲动力。 与此同时，随着中慧生物被纳入新一轮港股通标的名单，市场对公司的关注度亦出现明显提升。自1月 13日以来，公司股价强势上行，突破50港元关口，近十个交易日累计上涨26.47%，成交量同步显著放 大，显示增量资金正持续流入。在产品获批的利好消息驱动下，公司流动性预期持续改善，有望进一步 强化公司在资本市场的吸引力。 前瞻布局亚单位疫苗技术路线精准填补流感疫苗市场空白 当前，全球流感活动强度持续走高，而我国流感疫苗接种率仍远低于国际水平，这一巨大差距构成了长 期的结构性增长空间。 世卫组织报告显示，自2025年10月以来，全球流感活动强度持续攀升，甲型H3N2亚型流感病毒K亚分 ...

近日，中慧生物-B(02627)迎来又一项里程碑式进展——全国首款且唯一的全人群三价流感病毒亚单位 疫苗成功获批上市。 此前，公司的四价流感亚单位疫苗(慧尔康欣®)已率先实现全人群覆盖，成为中国首款且唯一一款获批 上市的全人群全剂量四价流感病毒亚单位疫苗。此次三价疫苗的成功获批，标志着公司在亚单位流感疫 苗这一优势赛道构建起更加全面的产品矩阵，不仅能够灵活适配多元化的公共卫生需求与市场偏好，也 将为公司业绩的持续兑现与价值重估注入强劲动力。 与此同时，随着中慧生物被纳入新一轮港股通标的名单，市场对公司的关注度亦出现明显提升。自1月 13日以来，公司股价强势上行，突破50港元关口，近十个交易日累计上涨26.47%，成交量同步显著放 大，显示增量资金正持续流入。在产品获批的利好消息驱动下，公司流动性预期持续改善，有望进一步 强化公司在资本市场的吸引力。 前瞻布局亚单位疫苗技术路线 精准填补流感疫苗市场空白 当前，全球流感活动强度持续走高，而我国流感疫苗接种率仍远低于国际水平，这一巨大差距构成了长 期的结构性增长空间。 世卫组织报告显示，自2025年10月以来，全球流感活动强度持续攀升，甲型H3N2亚型流感病毒K亚 ...

智通财经APP讯，中慧生物-B(02627)发布公告，中国国家药品监督管理局已批准本集团针对所有年龄组 别的三价流感病毒亚单位疫苗的新药申请。 截至本公告日期，该款疫苗成为中国首款且唯一一款获批上市的全人群全剂量三价流感病毒亚单位疫 苗。该产品在传统病毒裂解疫苗的基础上进行重大升级，具有保护全面、组分抗原纯度高、不良反应风 险低等优势。 ...

截至本公告日期，该款疫苗成为中国首款且唯一一款获批上市的全人群全剂量三价流感病毒亚单位疫 苗。该产品在传统病毒裂解疫苗的基础上进行重大升级，具有保护全面、组分抗原纯度高、不良反应风 险低等优势。 中慧生物-B(02627)发布公告，中国国家药品监督管理局已批准本集团针对所有年龄组别的三价流感病 毒亚单位疫苗的新药申请。 ...

格隆汇1月30日丨中慧生物-B(02627.HK)发布公告，国家药监局已批准集团针对所有年龄组别的三价流 感病毒亚单位疫苗的新药申请。 截至本公告日期，该款疫苗成为中国首款且唯一一款获批上市的全人群全剂量三价流感病毒亚单位疫 苗。该产品在传统病毒裂解疫苗的基础上进行重大升级，具有保护全面、组分抗原纯度高、不良反应风 险低等优势。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告由江蘇中慧元通生物科技股份有限公司（「本公司」或「中慧生物」，連同其 附屬公司，統稱「本集團」）自願刊發，以告知本公司股東及潛在投資者有關本集 團最新業務發展的資料。 本公司董事（「董事」）會（「董事會」）欣然宣佈，中國國家藥品監督管理局（「國家 藥監局」）已批准本集團針對所有年齡組別的三價流感病毒亞單位疫苗的新藥申 請。 截至本公告日期，該款疫苗成為中國首款且唯一一款獲批上市的全人群全劑量三 價流感病毒亞單位疫苗。該產品在傳統病毒裂解疫苗的基礎上進行重大升級，具 有保護全面、組分抗原純度高、不良反應風險低等優勢。 Ab&B Bio-Tech CO., LTD. JS 江蘇中慧元通生物科技股份有限公司 （於中華人民共和國成立的股份有限公司） （股份代號：2627） 自願性公告 我們是一家總部位於中國的疫苗公司，致力於創新疫苗及採用新技術方法的傳統 疫苗的研發、製造及商業化。我們密切追蹤傳染病的全球 ...